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Abstract
Furunculosis caused by infection with Aeromonas salmonicida subsp. salmonicida has been a known threat to aquaculture
for more than a century. Efficient prophylactic approaches against this disease are essential for continued growth of
salmonid aquaculture. Since the introduction of successful oil-adjuvanted vaccines in the early 1990’s, a number of studies
have been published on the protective as well as adverse effects of these vaccines. Most studies focus on vaccination of
salmon (Salmo salar). However, rainbow trout (Oncorhynchus mykiss) are also very susceptible to infection and are
vaccinated accordingly. In this study we have examined the protection against infection with a Danish strain of A.
salmonicida in both vaccinated and non-vaccinated rainbow trout. A commercial and an experimental auto-vaccine were
tested. The protective effects of the vaccines were evaluated through an A. salmonicida challenge 18 weeks post
vaccination. Both vaccines resulted in a significantly increased survival in the vaccinated fish during a 28 day challenge
period relative to non-vaccinated fish (P = 0.01 and P = 0.001 for the commercial and experimental vaccine, respectively).
Throughout the entire experiment, the presence of specific antibodies in plasma was monitored using ELISA. A significant
increase in specific antibody levels was seen in fish vaccinated with both vaccines during the 18 weeks between vaccination
and challenge. Within 3 days post challenge, a significant decrease in specific antibodies occurred in vaccinated fish. A
positive correlation was found between mean levels of specific antibodies pre challenge and overall survival. This
correlation, along with the observed depletion of antibodies during the initial phase of infection, suggests that specific
antibodies play an essential role in vaccine mediated protection against A. salmonicida in rainbow trout.
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Introduction
Aeromonas salmonicida subsp. salmonicida (hereafter referred to as A.
salmonicida) has been known as the causative agent of furunculosis
since the first cases were described in the late 19th century [1].
With the emergence of modern aquaculture, this Gram-negative
bacterium has developed into one of the most significant bacterial
infections in cultured fish across the world, affecting a wide range
of host species [2]. This has resulted in substantial economic losses,
particularly in the production of salmonid species. In order to
control the disease, great efforts have been put into developing
efficient prophylactic tools to prevent outbreaks in aquaculture.
Initial studies on oral vaccination of cutthroat trout proved
successful after periods of continuous immunization [3]. Immer-
sion has also been proven to provide protection against mortalities
in Chinook salmon, rainbow trout and Atlantic salmon [4–6].
However, other experiments in Atlantic salmon have since
demonstrated limited long-term effects of both oral and immersion
vaccination when compared to intraperitoneal (i.p.) injection of
adjuvanted vaccines [7]. Such short term protection will not meet
the needs of modern aquaculture, since reduced long-term
protection will result in an increased need for antibiotics during
disease outbreaks, and an increase in disease related mortalities.
Several studies have investigated the protection provided by
adjuvanted i.p. injected vaccines against A. salmonicida. Early on,
studies using injected vaccines in brook trout and brown trout
reported long-lasting, effective protection when using a mineral oil
adjuvant [8]. Later studies performed in Atlantic salmon have
shown similar results. Using oil-adjuvanted vaccines, a long-term,
high level of protection was seen for up to at least 6 months post
vaccination, along with significantly elevated antibody levels
against whole-cell bacteria and membrane proteins [9–11].
Studies have also been done on the antibody response of
rainbow trout towards various preparations of extracellular
products [12,13]. However, these studies conclude that the
response is limited in effect. Neither of these two studies includes
survival data.
The oil-adjuvanted bacterin based vaccine has now become the
main one for vaccinations of salmonids against A. salmonicida in
commercial aquaculture [14–16]. While providing long-lasting,
superior levels of protection, oil-adjuvanted vaccines have also
been shown to be associated with adverse effects, ranging from
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local observations such as pigmentation of tissues and intra-
abdominal adhesions [10,17,18] to systemic autoimmunity and
pathological changes in numerous tissues [19,20]. As with many
other studies, these have focused on salmon. Relative to salmon,
few vaccination studies have been performed on rainbow trout.
Recently, studies have shown that rainbow trout are more
susceptible to A. salmonicida than salmon [21]. A survey of
freshwater aquaculture have shown that few clinical infections
occur in freshwater [22]. It has been suggested that the trout are
infected in freshwater farms, carrying the infection to seawater,
where stress and high temperature may result in an outbreak of A.
salmonicida with resulting high mortality rates [15]. Vaccinations
are usually given prior to their transfer to sea cages, and reduce
mortalities in the vaccinated fish during infections [15,23].
The aim of this study was to look into protective effects of
vaccination of rainbow trout against A. salmonicida,focusing on
potential humoral effects. This was done by investigating the level
of protection induced against an experimental bacterial infection
by two different vaccines. The induction of specific antibody
production was examined post vaccination, and during the
bacterial challenge. Finally, a potential correlation between
antibody titer and survival during bacterial challenge was tested.
This should provide insight into potentially protective effects of




1500 rainbow trout were hatched and reared under pathogen-
free conditions at the Bornholm Salmon Hatchery (Nexø,
Denmark). The pathogen-free status was achieved by introducing
certified disinfected eggs into a recirculated system at the hatchery.
From the time of vaccination until time of challenge the fish were
kept at the hatchery. Here the fish were kept in 500 L, recirculated
tanks at 1461uC with a water flow of 25 L/min, and a
photoperiod of 7 hours per day. The fish were fed 1% of body
weight daily. Before bacterial challenge, the fish were transferred
to the experimental facilities at the University of Copenhagen in
Frederiksberg, Denmark. Before initiating the challenge, the
pathogen-free status was confirmed by standard bacteriological
examination methods in the laboratory. The Committee for
Animal Experimentation, Ministry of Justice, Denmark, approved
this study under license nr. 2012/561-147. The study was
conducted according to the ethical guidelines stated in the license.
Experimental auto vaccine
A Danish strain of Aeromonas salmonicida subsp. salmonicida
(040617-1/1A, challenge strain) was grown in heart infusion broth
(infusion made from 50% v/w beef heart, 1% v/w Bacto Tryptose,
0.5% v/w NaCl, pH 7.4) for 48 h at a constant temperature of
20uC with continuous shaking. The number of colony forming
units (CFU) per ml was estimated by triplicate plating of a ten-fold
dilution series of the bacterial culture. The culture was then
inactivated by addition of formalin to a final volume of 2%, after
which the inactivation was confirmed by a series of subsequent
plating on blood agar plates which yielded no CFU. After washing
in phosphate buffered saline (PBS), the bacterin was adjusted to
46109 CFU/ml in PBS. Immediately prior to administration, the
bacterin was thoroughly mixed 1:1 with Freund’s incomplete
adjuvant (Sigma-Aldrich- F5506). An injection dose of a total of
50 ml experimental vaccine per fish therefore contained
16108 CFU.
Vaccinations
Before vaccination, the fish (9.360.8 grams) were anaesthetized
by immersion in Benzoak VET (ACD Pharmaceuticals AS)
(56 mg/L, aerated water). Fish were vaccinated and grouped as
follows: I) 300 fish were kept as unhandled controls, II) 300 fish
were vaccinated intraperitoneally (i.p.) with 50 ml of commercial
furunculosis vaccine (AlphaJectH 3000, PHARMAQ AS, Over-
halla, Norway), III) 300 fish were injected i.p. with 50 ml
AlphaJectH adjuvant (PHARMAQ AS, Overhalla, Norway), IV)
300 fish were injected i.p. with 50 ml experimental vaccine, V) 300
fish were injected i.p. with 50 ml Freund’s incomplete adjuvant in
PBS (1:1).
The commercially available AlphaJect 3000 vaccine is a
trivalent vaccine containing a formaline-inactivated strain of A.
salmonicida subsp. salmonicida as well as a strain of both Vibrio
anguillarum serotype O1 and O2a, mixed with a liquid paraffin
adjuvant.
The fish were kept for 129 days at 14uC post vaccination, a total
of 1806 degree days, before challenge.
Sampling
On the day of vaccination, blood samples were taken from 10
unhandled, unvaccinated fish. Subsequently, blood samples were
taken 3, 10 and 18 weeks post vaccination, as well as 1, 3 and 28
days post infection from 5 fish from each experimental group. Fish
were euthanized in an overdose of MS-222 (200 mg/L) (Sigma-
Aldrich Inc.), after which blood was drawn from the Vena caudalis
using a 25G needle, and a heparinized syringe. The sample was
then centrifuged at 4000G for 10 min. The plasma fraction was
transferred to separate tubes, and kept at 280uC until they were
processed for ELISA measurement of antibody content.
Bacterial challenge
Fish were transported from the hatchery to the experimental
infection facilities at the University of Copenhagen, and upon
arrival each experimental group was transferred into duplicate
200 L tanks each holding 30 fish, one tank for monitoring
mortality and one holding 30 fish for sampling during the
challenge experiment. The fish were left to acclimatize for 18 days
at a constant room temperature of 14uC before the challenge was
started. The fish were fed to satiation daily. Immediately prior to
challenge, the average weight of the fish was 32.661.6 grams
(n= 30).
A challenge dose of the A. salmonicida challenge isolate was
grown as described above, resulting in 1.26108 CFU/ml. A bath
challenge was performed by transferring fish from each tank to
separate tanks containing a 3 L, 1:20 dilution of the bacterial
suspension (66106 CFU/ml). The exposure period was 1 hour,
during which a constant flow of air was provided and the fish were
monitored closely. After challenge the fish were transferred to their
original tanks, and kept here for 28 days. The fish were monitored
several times a day. Fish displaying a clear lack of appetite, isolated
behavior, dark coloration and difficulties maintaining equilibrium
were regarded as moribund and euthanized (200 mg MS-222/l).
Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA was performed with all collected plasma as described by
Raida, Nylen & Holten-Andersen [24]. Briefly, wells on microtiter
plates (NUNC Maxisorp, Thermo Fisher Scientific Inc.) were
coated overnight at 4uC with a sonicate of the A.salmonicida
challenge strain by adding the sonicate suspended in bicarbonate
buffer (pH 9.6)(Sigma-Aldrich Inc.) at a concentration of 5 mg
antigen protein/ml. Each well was then washed in 250 ml washing
Role of Specific Antibodies in Protection in Trout
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buffer (PBS+0.2% Tween 20), incubated for 1 hour in blocking
buffer (PBS+0.1% Tween 20+2% bovine serum albumin (BSA))
and subsequently washed in 250 ml washing buffer. All washing
steps consisted of 3 washes in wash buffer.
The antibody titers were assayed by serial 5-fold dilutions. All
samples were processed in duplicate. Dilutions were made with
assay diluent (PBS+1% BSA+1% Tween 20), and a volume of
100 ml was added to each duplicate well and incubated over night
at 4uC. On each plate, 4 wells were incubated with pure diluent
instead of diluted sample, for measurement of background
absorbance. An additional total of 8 wells were incubated with
two different internal standard plasma samples for interplate
calibration.
After wash, 100 ml mouse-anti-salmonid Ig (AbD Serotec,
diluted 1:500) was added to each well, and left at room
temperature for 1 h on a rotary shaker. After a subsequent
washing step, 100 ml horseradish-peroxidase labeled rabbit-anti-
mouse Ig (AbD Serotec, diluted 1:500) was added, and the plate
was placed on the shaker at room temperature for 1 h. Each well
was finally washed again before 100 ml TMB PLUS substrate
(AbD serotec) was added. The plate was placed on the rotary
shaker, and monitored for peroxidase reaction for 10 minutes.
The reaction was then stopped, by adding 100 ml 1 M HCl, and
the plate was analyzed in an ELISA plate-reader (Epoch, BioTek
Instruments Inc.) at 450 nm. During subsequent analysis, the
average background absorbance for each plate was subtracted
from the measured absorbance from the sample measurements of
that plate. For statistical analysis, the average optical density (OD)
measured from the duplicate 1:25 dilution of each sample was
used. For calculation of specific antibody titers, the average value
for each dilution step was plotted for each individual in each group
(y-axis) against the log10-transformed dilution steps (x-axis). Linear
regression was performed on the descending, linear section of the
resulting sigmoidal plot. The average measured background values
relevant for each sample were plotted as a horizontal line, and the
titer for each fish was defined as the x-coordinate for the
intersection between the regression –line and the average
background.
Statistical analysis
All statistical analysis was performed using GraphPad Prism 5
(GraphPad Software, Inc.).
Mortality data were analyzed using the Kaplan-Meier method
to analyze the survival curves. Groups were examined against each
other using the log-rank test to test for significant differences. The





ELISA results in fig. 2 were examined using a one-way ANOVA
with a Tukey post test to identify significant differences between
groups. Due to non-Gaussian distribution of data, ELISA titers
were analyzed using Kruskal-Wallis, with Dunn’s post test for
differences between between groups. Correlation analysis was
performed using the Pearson method. In all statistical analysis, P-
values,0.05 were considered statistically significant.
Results
Bacterial challenge
The results from the bacterial challenge with A. salmonicida are
shown in fig. 1. The onset of mortality was 3 days post challenge
for all infected groups. Mortalities accumulated within the first 9
days post challenge, and then settled with little additional increase
for the remainder of the challenge period. Both vaccines gave
significant reductions in mortality compared to the non-vaccinated
control group, with an RPS of 63.48% (P=0.001) for the
experimental auto vaccine and 49.69% (P= 0.01) for the
commercial vaccine. Additionally, both vaccines showed signifi-
cantly reduced mortalities compared to their respective adjuvant
formulations (P = 0.0001 and P=0.02 for experimental and
commercial formulation, respectively). There was no significant
difference between the two vaccines.
ELISA
The levels of specific antibodies were monitored at 7 different
time points: immediately prior to vaccination, 3, 10 and 18 weeks
post vaccination, and 1, 3 and 28 days post challenge. The results
are shown in fig. 2. At all three time points between vaccination
and challenge the experimental vaccine resulted in a significantly
increased antibody level compared to non-vaccinated controls,
while the commercial vaccine showed significantly increased
antibody levels relative to non-vaccinated controls at 10 weeks
post vaccination. None of the two adjuvant injected groups gave
significant increases in antibody levels compared to non-vaccinat-
ed controls. A significant drop in absorbance was seen for the
Figure 1. Survival curves from bacterial challenge. Survival curves representing the outcome of the bacterial challenge. N = 30 for each group,
except AlphaJect 3000 (N= 28). The two vaccinated groups showed significantly higher survival than infected controls (P = 0.001 and 0.01 for
experimental vaccine and AlphaJect 3000, respectively), as well as their respective adjuvants (P = 0.0001 and 0.02 for experimental vaccine and
AlphaJect 3000, respectively). Asterisks indicate statistically significant difference between treated group and infected controls (* = P,0.05,
** = P,0.01).
doi:10.1371/journal.pone.0046733.g001
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experimental vaccine between day 1 and 3 post challenge. No
decrease was seen in the commercial vaccine during the same
period. Fig. 3 shows a comparison of the calculated antibody titers
for each group at each time point. Antibody titers displayed non-
Gaussian distribution within groups, and were analyzed using the
non-parametric Kruskal-Wallis method. At 10 weeks post vacci-
nation the antibody titers of both vaccines were significantly higher
than that of the control group.
Correlation between ELISA and challenge data
Fig. 4 shows the result of plotting the survival of each
experimental group against the average antibody level measured
for the respective groups. A statistically significant, positive
correlation was found between increasing antibody and increasing
survival (P = 0.046, r = 0.885).
Discussion
The aims of this study were to assay the level of protection
provided by the two different vaccines against infection with A.
salmonicida, to investigate the development of specific antibody
responses and to get an insight into the potential protection
afforded by these antibody responses. Several studies on the effects
of vaccination have been performed on salmon, possibly due to
their economic role in modern aquaculture. However, some works
have focused on rainbow trout, from the initial attempts on
vaccination made by Duff in the 1940’s [3], over later
immunization studies by Krantz et al. [8], and on to the work of
Figure 2. Specific antibody response. Figures 2A–F show the results of the ELISA performed on sera collected from each experimental group at
each of the 7 sampling time points. Empty diamond: Pre vaccination Filled square: control, filled diamond: experimental vaccine, Filled circle:
Freunds incomplete adjuvant, Filled upward facing triangle: AlphaJect 3000, Filled downward facing triangle: PHARMAQ adjuvant. ANOVA analysis of
ELISA results were performed on the measured absorbance of the separate 1:25 dilutions in each group. Asterisks indicate statistically significant
difference between treated group and infected controls (* = P,0.05, ** = P,0.01, *** = P,0.001). All data shown are mean absorbance 6 SEM.
doi:10.1371/journal.pone.0046733.g002
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Hastings, Stapleton and Ellis on the antibody responses towards
extracellular products of A. salmonicida [12,13]. This study was
initiated to provide a collected view of the role of antibodies in the
induction of protection induced by the dominant oil adjuvanted
i.p. vaccination of rainbow trout.
The results from the bacterial challenge experiment show that
the vaccinated rainbow trout in this study were significantly
protected relative to the non-vaccinated ones. While the graph
illustrates that all groups exhibit a similar timeframe between the
onset and the end of mortality, the two vaccinated groups show a
low mortality within this timeframe, whereas the adjuvant groups
and the infected control undergo a steep decline in survival over
the same period of time. Similar patterns are seen in studies
conducted on salmon both after bath [11] and co-habitation
challenges [7,10]. This could indicate that a high level of
immediate protection during the earliest stages of infection is
required for successful survival during infection. A possible source
of protection is a competent humoral immune barrier, such as a
readily available pool of specific antibodies. The significant levels
of protection in this experiment are seen 4 months post
vaccination. Previous studies by Midtlyng et al. have shown
significant protection for up to 6 months in Atlantic salmon
vaccinated with oil-adjuvanted vaccines against A. salmonicida [10].
Both vaccinated groups developed significantly increased levels
of specific antibodies, able to recognize a sonicate of the bacterial
challenge strain during the first 10 weeks post vaccination. The
fish vaccinated with the experimental vaccine reaches significantly
increased antibody levels after 3 weeks, and continues to exhibit a
significant increase during the remaining 15 weeks until the
bacterial challenge. The differences in antibody levels between the
experimental and the commercial vaccine could, in part, be due to
the fact that the bacterial strain used in the vaccine and the ELISA
is identical. The results are similar to those seen in S. salar after
vaccination with both oil- and aluminum salt-adjuvanted vaccines
[9,25]. Erdal & Reitan [9] measured the antibody levels towards
whole bacteria, as well as both A-layer protein and lipopolysac-
charide. In their studies antibody levels against whole bacteria
were significantly elevated at 3 weeks post vaccination, and
remained high for the remainder of their 8 week experimental
period. Antibody levels against the more specific bacterial
components display a less consistent response during the same
time period. Midtlyng et al. also reported that salmon vaccinated
with an oil-adjuvanted vaccine, showed increasing antibody titers
throughout a 6 month period [10]. In the present experiment, the
commercial vaccine reached a significant increase after 10 weeks.
However, at 18 weeks post vaccination, the antibody levels of the
commercial vaccine were no longer significantly different from
that of the non-vaccinated controls. They are, however, still
elevated compared to the non-vaccinated controls. Krantz et al.
showed elevated antibody levels in brown trout after an oil
adjuvanted vaccination, sustaining the increased levels for at least
24 months [8]. Bricknell et al. showed elevated antibody levels after
un-adjuvanted vaccination of salmon, lasting at least 9 months
[11]. The same study reports vaccine induced protection 9 months
after vaccination, well beyond the timeline presented in this study.
Another interesting observation to be made is the significant
decrease in the level of antibodies seen in the fish vaccinated with
the experimental vaccine between day 1 and day 3 post challenge.
Bricknell et al. report similar findings in salmon [11]. Their study
reports that the development of antibody titers against iron-
regulated outer membrane proteins and polysaccharides in
vaccinated salmon appears to be limited by a bacterial challenge
when compared to non-challenged, vaccinated salmon. They
propose several possible explanations. One of these is that the
decrease in plasma antibody levels could be due to formation of
antibody:antigen complexes, reducing the number of free,
circulating antibodies. The authors later suggest the role of
immunosuppressing serine proteases [26]. However, depending on
the turnover of circulating antibodies, taking into account the
timeframe of just 2 days and the fact that the decrease occurs at
Figure 3. Antibody titers. Mean calculated titers 6 SEM for each
group at each time point. The titers were calculated as described in the
main text. Differences in antibody titer between control and treated
groups were analyzed using the Kruskal-Wallis method. Asterisks
indicate statistically significant difference between treated group and
infected controls (* = P,0.05, ** = P,0.01). See legend for identification
of the experimental groups.
doi:10.1371/journal.pone.0046733.g003
Figure 4. Correlation between antibodies and survival. Figure 3
shows a xy-plot of the survival of each group (N= 30, except AlphaJect
3000 (N= 28)) and the average measured absorbance in the 1:25
dilution of individual plasma samples from fish in each group (N=5).
Plasma samples are taken 18 weeks post vaccination, immediately prior
to bacterial challenge. The correlation was calculated using the Pearson
method: P = 0.046, r = 0.885.
doi:10.1371/journal.pone.0046733.g004
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the time of the onset of mortality, we believe that the decrease seen
in this study could be due to a depletion of antibodies, either in
formation of antigen:antibody complexes, or opsonization of such
complexes.
When comparing the antibody levels in fig. 2 with the calculated
antibody titers shown in fig. 3, it is clear that both vaccines induce
development of large pools of specific antibodies, indicated by the
large increases in antibody titer. Comparing the survival data
shown in fig. 1 with the antibody measurements shown in fig. 2,
the two vaccinated groups show both the highest survival
percentages, as well as the highest antibody titers. Since the
plasma samples were taken immediately prior to the bacterial
challenge, these antibody titers represent the available pools of
specific antibodies at the time of challenge for each group. This
again proves a possible connection between the survival data seen
in fig. 1 and the results of the ELISA shown in fig. 2, since these
pools reflect the potential protective antibody mediated defense
against the pathogen.
Recently, ELISA performed on blood samples from salmon
vaccinated against A. salmonicida was proposed as a means of
conducting vaccine batch testing by Romstad, et al [25]. In their
study, a statistically significant, positive correlation was found
between increased levels of specific antibodies and increased
survival in the vaccinated fish. Bricknell et al. also find correlations
between specific antibodies and protection [11]. Our results
provide basis for a similar analysis, and show a significant
correlation between antibody level and survival.
The work presented here has not dealt with the possible cell-
mediated immune response against A. salmonicida. However, we
have shown a significant level of protection against infection
induced by a commercial, as well as an experimental vaccine. Both
vaccines induced production of specific antibodies, reaching
significantly elevated levels compared to those of non-vaccinated
controls within 10 weeks of vaccination. Two factors indicate a
connection between the antibody production and protection
induced by the vaccinations: a positive correlation between
antibody level prior to challenge and survival during challenge,
as well as an apparent depletion of plasma antibodies in the early,
crucial phase of the infection. These two factors correlate well with
the experiences from studies on vaccination of salmon mentioned
earlier, and emphasize the protective role of specific antibodies
against A. salmonicida. The exact nature of this protective effect
remains undisclosed, and future studies are needed to determine
the details of the protective effects, as well as potential interplay
between humoral and cell-mediated immune responses. Hopefully
this will pave the way for future studies on vaccination of rainbow
trout against A. salmonicida.
Acknowledgments
The authors would like to thank aquaculture assistants John Haakonsson
and Claus Jespersen at Bornholm Salmon Hatchery for rearing the fish.
We would also like to thank Johnny Schoubo Jensen at the Institute of
Veterinary Disease Biology, University of Copenhagen for assistance with
the growth media used for cultivating the bacteria. Finally, we would like to
thank Bjørn Brudeseth at PHARMAQ AS for kindly providing vaccine,
adjuvant and advice. This work was performed as part of the Danish Fish
Immunology Research Center & Network (DAFINET).
Author Contributions
Conceived and designed the experiments: KRV MKR LHOA. Performed
the experiments: KRV MKR. Analyzed the data: KRV MKR.
Contributed reagents/materials/analysis tools: MKR KRV IDA. Wrote
the paper: KRV MKR. Provided critical review of the manuscript: KRV
MKR LHOA IDA.
References
1. Emmerich R, Weibel E (1894) U¨ber eine durch Bacterien erzeugte Seuche unter
den Forellen. Archiv fu¨r Hygiene 21: 1–21.
2. Bernoth EM, editor (1997) Furunculosis: The History of the Disease and of
Disease Research: Academic Press. 21 p.
3. Duff DCB (1942) The oral immunization of trout against Bacterium salmonicida.
Journal of Immunology 44: 87–94.
4. Johnson KA, Amend DF (1984) Potential for Immersion Vaccination against
Aeromonas-salmonicida. Journal of Fish Diseases 7: 101–105.
5. Rodgers CJ (1990) Immersion Vaccination for Control of Fish Furunculosis.
Diseases of Aquatic Organisms 8: 69–72.
6. Adams A, Auchinachie N, Bundy A, Tatner MF, Horne MT (1988) The
Potency of Adjuvanted Injected Vaccines in Rainbow Trout (Salmo gairdneri
Richardson) and Bath Vaccines in Atlantic Salmon (Salmo salar L) against
Furunculosis. Aquaculture 69: 15–26.
7. Midtlyng PJ, Reitan LJ, Lillehaug A, Ramstad A (1996) Protection, immune
responses and side effects in Atlantic salmon (Salmo salar L) vaccinated against
furunculosis by different procedures. Fish & Shellfish Immunology 6: 599–613.
8. Krantz GE, Heist CE, Reddecli.Jm (1963) Development of Antibodies against
Aeromonas salmonicida in Trout. Journal of Immunology 91: 757–&.
9. Erdal JI, Reitan LJ (1992) Immune response and protective immunity after
vaccination of Atlantic salmon (Salmo salar L.) against furunculosis. Fish &
Shellfish Immunology 2: 99–108.
10. Midtlyng PJ, Reitan LJ, Speilberg L (1996) Experimental studies on the efficacy
and side-effects of intraperitoneal vaccination of Atlantic salmon (Salmo salar L.)
against furunculosis. Fish & Shellfish Immunology 6: 335–350.
11. Bricknell IR, King JA, Bowden TJ, Ellis AE (1999) Duration of protective
antibodies, and the correlation with protection in Atlantic salmon (Salmo salar L.),
following vaccination with an Aeromonas salmonicida vaccine containing iron-
regulated outer membrane proteins and secretory polysaccharide. Fish &
Shellfish Immunology 9: 139–151.
12. Hastings TS, Ellis AE (1988) The Humoral Immune Response of Rainbow
Trout, Salmo gairdneri Richardson, and Rabbits to Aeromonas salmonicida Extracellular
Products. Journal of Fish Diseases 11: 147–160.
13. Ellis AE, Stapleton KJ, Hastings TS (1988) The Humoral Immune Response of
Rainbow Trout (Salmo gairdneri) Immunized by Various Regimes and
Preparations of Aeromonas salmonicida Antigens. Veterinary Immunology and
Immunopathology 19: 153–164.
14. Sommerset I, Krossoy B, Biering E, Frost P (2005) Vaccines for fish in
aquaculture. Expert Review of Vaccines 4: 89–101.
15. Pedersen K, Skall HF, Lassen-Nielsen AM, Nielsen TF, Henriksen NH, et al.
(2008) Surveillance of health status on eight marine rainbow trout, Oncorhynchus
mykiss (Walbaum), farms in Denmark in 2006. J Fish Dis 31: 659–667.
16. Plant KP, LaPatra SE (2011) Advances in fish vaccine delivery. Developmental
and Comparative Immunology 35: 1256–1262.
17. Midtlyng PJ (1996) A field study on intraperitoneal vaccination of Atlantic
salmon (Salmo salar L) against furunculosis. Fish & Shellfish Immunology 6: 553–
565.
18. Mutoloki S, Alexandersen S, Evensen O (2004) Sequential study of antigen
persistence and concomitant inflammatory reactions relative to side-effects and
growth of Atlantic salmon (Salmo salar L.) following intraperitoneal injection with
oil-adjuvanted vaccines. Fish & Shellfish Immunology 16: 633–644.
19. Koppang EO, Bjerkas I, Haugarvoll E, Chan EK, Szabo NJ, et al. (2008)
Vaccination-induced systemic autoimmunity in farmed Atlantic salmon.
J Immunol 181: 4807–4814.
20. Haugarvoll E, Bjerkas I, Szabo NJ, Satoh M, Koppang EO (2010)
Manifestations of systemic autoimmunity in vaccinated salmon. Vaccine 28:
4961–4969.
21. Holten-Andersen L, Dalsgaard I, Buchmann K (2012) Baltic salmon, Salmo salar,
from Swedish river Lule alv is more resistant to furunculosis compared to
rainbow trout. PLoS One 7: e29571.
22. Dalsgaard I, Madsen L (2000) Bacterial pathogens in rainbow trout, Oncorhynchus
mykiss (Walbaum), reared at Danish freshwater farms. Journal of Fish Diseases 23:
199–209.
23. Hastein T, Gudding R, Evensen O (2005) Bacterial vaccines for fish -an update
of the current situation worldwide. Dev Biol (Basel) 121: 55–74.
24. Raida MK, Nylen J, Holten-Andersen L, Buchmann K (2011) Association
between Plasma Antibody Response and Protection in Rainbow Trout
Oncorhynchus mykiss Immersion Vaccinated against Yersinia ruckeri. PLoS One 6.
25. Romstad AB, Reitan LJ, Midtlyng P, Gravningen K, Evensen O (2011)
Development of an antibody ELISA for potency testing of furunculosis
(Aeromonas salmonicida subsp salmonicida) vaccines in Atlantic salmon (Salmo salar
L). Biologicals.
26. O’Dowd AM, Bricknell IR, Secombes CJ, Ellis AE (1999) The primary and
secondary antibody responses to IROMP antigens in Atlantic salmon (Salmo salar
L) immunised with A(+) and A(2) Aeromonas salmonicida bacterins. Fish & Shellfish
Immunology 9: 125–138.
Role of Specific Antibodies in Protection in Trout
PLOS ONE | www.plosone.org 6 October 2012 | Volume 7 | Issue 10 | e46733
